ID
25747
Beschrijving
Study ID: 101468/169 Clinical Study ID: 101468/169 Study Title:A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment with Ropinirole CR as Adjunctive Therapy in Patients with Parkinson's Disease who are not Optimally Controlled on L-dopa Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00381472 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Parkinson Disease This is the L-Dopa Medication form.
Trefwoorden
Versies (2)
- 17-09-17 17-09-17 -
- 28-09-17 28-09-17 -
Houder van rechten
GlaxoSmithKline
Geüploaded op
17 september 2017
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
GSK Ropinirole in Patients Suffering from Parkinsons Disease L-Dopa Medication 101468/169 NCT00381472
GSK Ropinirole in Patients Suffering from Parkinsons Disease L-Dopa Medication 101468/169 NCT00381472
Similar models
GSK Ropinirole in Patients Suffering from Parkinsons Disease L-Dopa Medication 101468/169 NCT00381472
C0013227 (UMLS CUI [1,2])
C0023570 (UMLS CUI [1,3])
C0023570 (UMLS CUI [1,2])
C0023570 (UMLS CUI [1,3])
C0869039 (UMLS CUI [1,4])
C0013227 (UMLS CUI [1,2])
C0023570 (UMLS CUI [1,3])
C0013227 (UMLS CUI [1,2])
C0023570 (UMLS CUI [1,3])
C0808070 (UMLS CUI [1,2])
C0023570 (UMLS CUI [1,3])
C0023570 (UMLS CUI [1,2])
C0023570 (UMLS CUI [1,2])